UNASSIGNED: Background @entity1073 is generally incurable. Initial treatment is not standardized but usually includes cytotoxic chemotherapy. @entity6985 , an immunomodulatory compound, and rituximab, an anti- @entity2225 antibody, are active in @entity1 with recurrent @entity1073 . We evaluated @entity6985 plus rituximab as a first-line therapy. Methods We conducted a single-group, multicenter, phase 2 study with induction and maintenance phases. During the induction phase, @entity6985 was administered at a dose of 20 mg daily on days 1 through 21 of every 28-day cycle for 12 cycles; the dose was escalated to 25 mg daily after the first cycle if no dose-limiting adverse events occurred during the first cycle and was reduced to 15 mg daily during the maintenance phase. Rituximab was administered once weekly for the first 4 weeks and then once every other cycle until disease progression. The primary end point was the overall response rate. Secondary end points included outcomes related to safety, survival, and quality of life. Results A total of 38 @entity1 were enrolled at four centers from July 2011 through April 2014. The median age was 65 years. On the basis of the Mantle Cell Lymphoma International Prognostic Index scores, the proportions of @entity1 with low-risk, intermediate-risk, and high-risk disease at baseline were similar (34%, 34%, and 32%, respectively). The most common grade 3 or 4 adverse events were @entity1398 (in 50% of the @entity1 ), @entity1910 (in 29%), @entity882 (in 13%), an @entity32 (" @entity5 flare") (in 11%), @entity417 (in 11%), serum sickness (in 8%), and fatigue (in 8%). At the median follow-up of 30 months (through February 2015), the overall response rate among the @entity1 who could be evaluated was 92% (95% confidence interval [CI], 78 to 98), and the complete response rate was 64% (95% CI, 46 to 79); median progression-free survival had not been reached. The 2-year progression-free survival was estimated to be 85% (95% CI, 67 to 94), and the 2-year overall survival 97% (95% CI, 79 to 99). A response to treatment was associated with improvement in quality of life. Conclusions Combination biologic therapy consisting of @entity6985 plus rituximab was active as initial therapy for @entity1073 . (Funded by Celgene and Weill Cornell Medical College; ClinicalTrials.gov number, NCT01472562 .).

@entity6985 plus Rituximab as Initial Treatment for XXXX .

@entity1 :: ('9606', 'Species') :: ['participants', 'patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammatory syndrome'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity1910 :: ('MESH:D005076', 'Disease') :: ['rash'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity2225 :: ('54474', 'Gene') :: ['CD20'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1073 :: ('MESH:D020522', 'Disease') :: ['mantle-cell lymphoma', 'Mantle-cell lymphoma'] @entity6985 :: ('MESH:C467567', 'Chemical') :: ['Lenalidomide', 'lenalidomide']
@entity1073 :: (MESH:D020522,Disease) :: ['Mantle-Cell Lymphoma']
